vs
Autonomix Medical, Inc.（AMIX）与Alaunos Therapeutics, Inc.（TCRT）财务数据对比。点击上方公司名可切换其他公司
Alaunos Therapeutics, Inc.自由现金流更多（$-3.0M vs $-3.0M）
Autonomix Medical是一家专注于心脏电生理领域的医疗科技企业，主要开发用于心律失常诊断与治疗的微创医疗设备，服务北美、欧洲地区的医疗机构与患者，致力于提升心律相关心脏疾病的诊疗效率与效果。
Alaunos Therapeutics是一家临床阶段生物技术企业，专注于开发用于治疗难治性实体瘤的新型T细胞受体免疫疗法，针对共有肿瘤抗原推进精准肿瘤学候选药物管线，通过自主研发与行业合作服务全球肿瘤患者群体。
AMIX vs TCRT — 直观对比
营收规模更大
TCRT
是对方的Infinity倍
$0
自由现金流更多
TCRT
多$9.0K
$-3.0M
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $3.0K |
| 净利润 | $-3.3M | — |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | — | — |
| 营收同比 | — | -40.0% |
| 净利润同比 | -20.2% | -20.5% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMIXTCRT
| Q4 25 | $0 | $3.0K | ||
| Q3 25 | $0 | $0 | ||
| Q2 25 | $0 | $0 | ||
| Q1 25 | $0 | $2.0K | ||
| Q4 24 | $0 | $5.0K | ||
| Q3 24 | $0 | $0 | ||
| Q2 24 | $0 | $4.0K | ||
| Q1 24 | — | $1.0K |
净利润AMIXTCRT
| Q4 25 | $-3.3M | — | ||
| Q3 25 | $-7.5M | $-1.2M | ||
| Q2 25 | $-3.3M | $-1.1M | ||
| Q1 25 | $-3.2M | $-1.1M | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.8M | $-1.1M | ||
| Q2 24 | $-2.7M | $-1.1M | ||
| Q1 24 | — | $-1.7M |
营业利润率AMIXTCRT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -54600.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -29150.0% | ||
| Q1 24 | — | -174200.0% |
净利率AMIXTCRT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -53650.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -28225.0% | ||
| Q1 24 | — | -168200.0% |
每股收益（稀释后）AMIXTCRT
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.55 | ||
| Q2 25 | — | $-0.63 | ||
| Q1 25 | — | $-0.67 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.70 | ||
| Q2 24 | — | $-0.71 | ||
| Q1 24 | — | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.9M | $1.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.6M | $2.2M |
| 总资产 | $10.2M | $3.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMIXTCRT
| Q4 25 | $9.9M | $1.4M | ||
| Q3 25 | $7.5M | $1.9M | ||
| Q2 25 | $8.6M | $2.9M | ||
| Q1 25 | $9.1M | $319.0K | ||
| Q4 24 | $11.8M | $1.1M | ||
| Q3 24 | $5.2M | $1.7M | ||
| Q2 24 | $6.8M | $2.5M | ||
| Q1 24 | — | $4.1M |
股东权益AMIXTCRT
| Q4 25 | $8.6M | $2.2M | ||
| Q3 25 | $6.4M | $2.8M | ||
| Q2 25 | $7.0M | $3.7M | ||
| Q1 25 | $8.1M | $1.1M | ||
| Q4 24 | $9.7M | $2.1M | ||
| Q3 24 | $3.0M | $2.7M | ||
| Q2 24 | $5.3M | $3.8M | ||
| Q1 24 | — | $4.8M |
总资产AMIXTCRT
| Q4 25 | $10.2M | $3.0M | ||
| Q3 25 | $7.9M | $3.7M | ||
| Q2 25 | $9.0M | $4.7M | ||
| Q1 25 | $9.8M | $2.1M | ||
| Q4 24 | $12.0M | $2.8M | ||
| Q3 24 | $5.4M | $3.5M | ||
| Q2 24 | $7.1M | $4.7M | ||
| Q1 24 | — | $6.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.0M | $-2.9M |
| 自由现金流经营现金流 - 资本支出 | $-3.0M | $-3.0M |
| 自由现金流率自由现金流/营收 | — | -98900.0% |
| 资本支出强度资本支出/营收 | — | 3266.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMIXTCRT
| Q4 25 | $-3.0M | $-2.9M | ||
| Q3 25 | $-3.8M | $-844.0K | ||
| Q2 25 | $-2.6M | $-701.0K | ||
| Q1 25 | $-2.6M | $-772.0K | ||
| Q4 24 | $-2.3M | $-5.0M | ||
| Q3 24 | $-1.6M | $-781.0K | ||
| Q2 24 | $-1.9M | $-1.7M | ||
| Q1 24 | — | $-1.9M |
自由现金流AMIXTCRT
| Q4 25 | $-3.0M | $-3.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-2.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.9M | — | ||
| Q1 24 | — | — |
自由现金流率AMIXTCRT
| Q4 25 | — | -98900.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度AMIXTCRT
| Q4 25 | — | 3266.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
